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From the Editor 
What is T.A.P.E.S. ? 
TAPES, the Center of Excellence for Technology Assessment and PharmacoEconomic 
Services, was created in order to help pharmaceutical and biotechnology companies 
assess economic value in a changing health care market place. TAPES is a non-profit 
organization funded by a grant from the Ben Franklin Partnership (BFP), an agency 
designated by the State of Pennsylvania to provide assistance to local 
pharmaceutical and biotechnology firms.  
TAPES is a cooperative venture between the Department of Health Policy at Thomas 
Jefferson University (TJU), and the Institute for Pharmaceutical Economics at the 
Philadelphia College of Pharmacy and Science (PCPS). I serve as the Director of 
TAPES, while Dr. Gary Erwin, the Vice President of the Department of Professional 
Programs at PCPS, is the Co-Director. We have created a structure for TAPES 
enabling TJU and PCPS to perform cost-effectiveness studies that help answer the 
question "Even though a drug or treatment modality is safe, is it worth doing ?"  
The primary goal of TAPES is to help biotechnology manufacturers conduct outcomes 
assessments for both new and established products. By conducting these studies, 
TAPES gives local companies the tools they need in order to prove that their products 
are not only safe, but also cost-effective.  
Creating new pharmaceutical and biotechnological products is not as easy as it used 
to be. With health care reform looming like a veritable Sword of Damocles over the 
heads of drug and biotechnology companies, consumers and payers are demanding 
that in this era of accountability, cost-effectiveness should apply not only to 
clinicians, but to product makers as well.  
Technology Assessment is a burgeoning field. Many observers believe that there may 
be too much expensive technology in today's medicine. The burden of proof as to the 
worth of new innovations now rests with the companies that produce them. For the 
giants of the industry, this task is daunting, but not impossible; for smaller firms it 
can be an overwhelming obstacle that, if not surmounted, could eventually lead to 
their elimination from the market place.  
The Philadelphia area is home to many such small firms. The Technology Council of 
Greater Philadelphia has 400 member companies-Route 202 alone, the famed 
"Medical Mile," is home to 30 biotechnology and medical start up firms. The State of 
Pennsylvania has demonstrated its commitment to these businesses by funding 
TAPES through the auspices of the Ben Franklin Partnership. TAPES provides its 
research consulting expertise to members of the Ben Franklin Partnership for 
relatively small fees as well as providing a host of other services, including: 
individual training sessions, courses in clinical trials and outcomes research, and 
periodic conferences.  
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One conference sponsored by TAPES and BFP entitled "Developing Health Care 
Products for Managed Care Purchasers," took place at Jefferson this past summer. 
Over 80 representatives of purchaser, provider, payer, and product groups attended 
in order to better understand the changing rules for developing biotechnology 
devices and pharmaceutical products in the context of managed care. Speakers 
focused on how outcomes research will play a major part in acceptance of and 
reimbursement for these products through a series of talks ranging from "The Role of 
Outcomes and Economic Research in Product Development," by Nelda Johnson, 
PharmD (TJU), to "Your Medical Device: Getting Started with the FDA," by Robert 
Mosenkis, President of CITECH, and "How Do Third Party Payers Decide Whether You 
Will Be Paid," by Jeffrey Lerner, Ph.D. (ECRI).  
The TAPES Center provides an invaluable service to local and national companies. In 
studying technology assessment, everyone wins. Companies market more sensible 
products, consumers get the most "bang for their buck," and payers get the sense 
that what they are paying for is worthwhile.  
I appreciate the great teamwork of Gary Erwin and the support he receives from Dr. 
Philip Gerbino, the Dean of PCPS. The future of TAPES is exciting, and I am looking 
forward to continuing the Jefferson tradition of a productive and beneficial 
relationship with PCPS. As always, I encourage members of the Jefferson community 
to contact me at extension 6969, or send me a letter sharing your thoughts. 
 
- David B. Nash  
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